Scarica l'app Stockscreener
5.75
0.52%
-0.03
Dopo l'orario di chiusura:
5.75
Precedente Chiudi:
$5.78
Aprire:
$5.79
Volume 24 ore:
1,572
Relative Volume:
0.15
Capitalizzazione di mercato:
$8.40M
Reddito:
-
Utile/perdita netta:
$-16.49M
Rapporto P/E:
-0.1941
EPS:
-29.6295
Flusso di cassa netto:
$-15.24M
1 W Prestazione:
-2.32%
1M Prestazione:
+12.09%
6M Prestazione:
+71.64%
1 anno Prestazione:
-17.86%
Intervallo 1D:
$5.75
$5.79
Intervallo di 1 settimana:
$5.64
$5.99
Portata 52W:
$1.90
$10.59
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Nome
Cns Pharmaceuticals Inc
Settore
Industria
Telefono
1-800-946-9185
Indirizzo
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
5.75 | 8.45M | 0 | -16.49M | -15.24M | -29.63 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-28 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | Iniziato | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie
CNS Pharmaceuticals Inc (CNSP) Stock Price, Quote, News & History - benzinga.com
PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company - globenewswire.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com
CNS Pharmaceuticals (CNSP) Outlines Strategic Shift Amid Unprofi - GuruFocus
A biotech is seeking cancer or brain therapies. CNS Pharmaceuticals lays out its plan. - Stock Titan
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference - Weatherford Democrat
CNS Pharmaceuticals CEO highlights new leadership team and strategy - Stock Titan
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com South Africa
Vertical Data: Downs Most Recently Served as CFO of CNS Pharmaceuticals >VDTA - Moomoo
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock - Investing.com
CNS Pharmaceuticals (CNSP) director buys 2,000 shares in open-market trade - Stock Titan
CNS Pharmaceuticals (CNSP) CEO converts 4,750 RSUs to stock - Stock Titan
CNS Pharmaceuticals (CNSP) lists director Michal with no reported trades - Stock Titan
Central Nervous System (CNS) Lymphoma Market Outlook Signals Expansion To $2.08 Billion Through 2030 - openPR.com
CNS Pharmaceuticals (CNSP) Climbs 7.18% to $5.52 as Biotech Buying Pressure IntensifiesSwing Trade Setups - vinanet.vn
Ikarian Capital (CNSP) discloses 9.9% beneficial ownership in CNS Pharmaceuticals - Stock Titan
CNSP Q2 2026 Earnings: Wider-than-Expected Loss of -$0.38 per Share Amid Clinical-Stage OperationsNet Profit Margin - vinanet.vn
CNS Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
CNS PHARMACEUTICALS ($CNSP) Releases Q2 2026 Earnings - Moomoo
CNS Pharmaceuticals Q2 net loss widens, cash rises after financing - TradingView
CNSP: Accelerated transformation and strong cash position support pipeline expansion and strategic growth - TradingView
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - accessnewswire.com
CNS Pharmaceuticals, Inc. Q2 2026: Net loss $2.59M, EPS $(0.38) — 10-Q Summary - TradingView
CNS Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
CNSP Q1 2026 Earnings: Loss of $7.30 Per Share Misses Estimates as Pre-Revenue Pipeline Spend Rises - vinanet.vn
CNS Pharmaceuticals Inc (CNSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Supernus & Indivior to merge in $2.2 billion CNS pharma deal - Voice of Healthcare
Supernus Pharmaceuticals and Indivior Pharmaceuticals to - globenewswire.com
CNS Pharmaceuticals Inc (CNSP) Cash Flow - TradingKey
CNS Pharmaceuticals Inc (CNSP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CNS Pharmaceuticals Inc (CNSP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CNS Pharmaceuticals Inc (CNSP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
CNSP|CNS Pharmaceuticals Inc|Price:5.230|Chg%:-0.160 - TradingKey
CNS Pharmaceuticals Inc (CNSP) Valuation: PE, PB & Fair Value Analysis - TradingKey
CNSP|CNS Pharmaceuticals Inc|Price:5.070|Chg%:-0.160 - TradingKey
CNS Pharmaceuticals Inc (CNSP) Institutional Confidence - TradingKey
CNS Pharmaceuticals Inc (CNSP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CNS Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CNSP - TradingView
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring a 37% Potential Upside in CNS Therapeutics - DirectorsTalk Interviews
CNS Pharmaceuticals Inc (CNSP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CNSP Q1 2026 Earnings: EPS Misses Estimates as Clinical Pipeline AdvancesBasic EPS Analysis - vinanet.vn
CNSP Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesEarnings Surprise Report - dars.gov.et
CNSP Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Drug Developer Navigates Clinical MilestonesEPS Guidance Update - vinanet.vn
CNS Pharmaceuticals(CNSP) Stock Options Chain | Quotes & News - Moomoo
CNS Pharmaceuticals Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Costs PersistShare Repurchase Impact - DonanımHaber
CNS Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as Biotech Focuses on Clinical Milestones - dars.gov.et
CNS Pharmaceuticals Announces Strategic Oncology-Neurology Realignment - TipRanks
CNS Pharmaceuticals posts investor presentation; details $22.5M financing and strategic pivot - TradingView
Strategic pivot at CNS Pharmaceuticals (NASDAQ: CNSP) backed by $22.5M PIPE - Stock Titan
CNS Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
Cns Pharmaceuticals Inc Azioni (CNSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):